logo-loader
viewPolarean Imaging PLC

Polarean Imaging eagerly awaiting readouts from its key phase III clinical trials

Polarean Imaging PLC's (LON:POLX) Richard Hullihen speaks to Proactive London's Andrew Scott following the news they've now completed patient enrolment for the phase III clinical trials of its MRI lung scan technology.

He says the trials are now in the image and statistical analysis stage, a process that is expected to take around 10 weeks and will conclude with a readout of the trial.

Quick facts: Polarean Imaging PLC

Price: 20 GBX

AIM:POLX
Market: AIM
Market Cap: £22.89 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Polarean Imaging PLC named herein, including the promotion by the Company of Polarean Imaging PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: AFC Energy's HydroX-Cell 'performs well' against rival PEM...

Headlines from the Proactive UK newsroom. AFC Energy (LON:AFC) says its high-current density alkaline fuel cell, called HydroX-Cell, performed well against rival PEM technology in a single fuel cell operation.  AFC says HydroX-Cells are also capable of using low grade (and low cost)...

on 7/11/19

2 min read